$LINE’s blockbuster IPO raised billions—but did it freeze out the truth? In this episode of Sue Wall Street, we unpack the class action lawsuit alleging Lineage misled investors about plunging demand, evaporating inventory, and a deep freeze in fundamentals. With private equity payouts, post-COVID market distortions, and a fired auditor, this case is a must-listen for IPO investors, pension funds, and anyone tracking Wall Street accountability. Expect deep dives, sharp takes, and frosty truths.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

When $FLYW’s stock plunged 37% in a single day, investors were blindsided. In this episode of Sue Wall Street, we break down the new class action lawsuit accusing Flywire of downplaying massive headwinds from international student visa caps while hyping their growth narrative. If you're into SaaS stocks, fintech drama, or shareholder rights, this one's for you. Expect insider breakdowns, sharp commentary, and red flags you don’t want to miss.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Was $FI’s explosive growth just a billing trick? In this episode of Sue Wall Street, we unpack the class action lawsuit alleging that Fiserv misled investors by calling forced migrations to its Clover platform "organic growth." Small businesses pushed off the Payeezy system didn’t stick around—and when they fled, the stock followed. If you're a fintech investor, shareholder advocate, or SEC rules junkie, this one's for you. Expect exposés, sharp analysis, and unraveling KPIs.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

When $DOW slashed its dividend by 50% after months of rosy forecasts, investors were left reeling—and a securities fraud lawsuit quickly followed. In this episode of Sue Wall Street, we unpack the allegations that Dow Inc. misled shareholders about financial stability, masking demand drops and oversupply issues in key markets. Perfect for retail investors, dividend chasers, and finance nerds who love a good Wall Street reckoning. Expect sharp commentary, deep dives, and corporate accountability.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

Biotech dreams turned into investor nightmares when $ALT stock plummeted 53% overnight after failing a key endpoint in its MASH drug trial. In this episode of Sue Wall Street, we break down the class action lawsuit accusing Altimmune of hyping results and misleading shareholders. Perfect for investors, biotech watchers, and legal buffs, this episode mixes deep-dive analysis with sharp commentary. Expect insider breakdowns, trial missteps, and the legal firestorm that followed.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

In this episode of Sue Wall Street, we expose the serious legal consequences of $XYZ insider trading—from multi-million dollar fines to decades behind bars. Whether you’re trading on a hot tip or just “sharing” info, the SEC and DOJ don’t play around. We break down tipping, penalties, and why ignorance won’t save you. Perfect for retail traders, finance professionals, and anyone at risk of overhearing the wrong thing at a backyard BBQ.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

In this episode of Sue Wall Street, we dig into the high-stakes world of insider trading—what it is, how to spot it, and how you can report it through the SEC Whistleblower Program. From shady trades to million-dollar rewards, we cover the process, anonymity options, and real risks of retaliation. If you're an investor, employee, or just someone with a suspicious eye, this guide is for you.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

$FLYE Fly-E Group soared on promises of urban mobility and government-backed safety programs—then crashed 87% in a day after battery explosions and revenue drops came to light. In this episode of Sue Wall Street, we expose the class action lawsuit alleging Fly-E misled investors about lithium battery risks and future growth. Perfect for EV investors, startup skeptics, and anyone watching the electric mobility space crash into regulatory reality.

Visit ZLK.com for more info.

In this episode of Sue Wall Street, we unpack what happens when company execs treat fiduciary duties like a suggestion not a requirement. From insider enrichment to reckless decisions masked as “business judgment,” we break down how shareholders get burned and how class actions try to restore accountability. If you’ve ever owned stock or trusted a CEO, this one’s for you. Great for retail investors, governance nerds, and legal-watchers.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

In this episode of Sue Wall Street, Cassie and Bill dive into the spectacular collapse of $ANRO Alto Neuroscience. After raising $119M in its 2024 IPO on hopes of revolutionizing psychiatry, its flagship drug ALTO-100 flunked a critical trial—sending shares plummeting nearly 70%. We unpack the lawsuit alleging misleading IPO documents, dig into the risks of precision medicine, and ask: was this hype or just heartbreak? Perfect for investors, biotech watchers, and anyone tracking Wall Street accountability.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.